260 related articles for article (PubMed ID: 30363418)
1. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
Martínez-Martín P; Rodríguez-Blázquez C; Forjaz MJ; Alvarez-Sánchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martínez-Castrillo JC; Mendoza-Rodríguez A; Moore HP; Rodríguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
Eur J Neurol; 2014 Mar; 21(3):519-24. PubMed ID: 24447695
[TBL] [Abstract][Full Text] [Related]
3. Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.
Watanabe H; Saiki H; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Maeda T; Shimo Y;
Mov Disord Clin Pract; 2020 May; 7(4):431-439. PubMed ID: 32373660
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale.
Martínez-Martín P; Rodríguez-Blázquez C; Mario Alvarez ; Arakaki T; Arillo VC; Chaná P; Fernández W; Garretto N; Martínez-Castrillo JC; Rodríguez-Violante M; Serrano-Dueñas M; Ballesteros D; Rojo-Abuin JM; Chaudhuri KR; Merello M
Parkinsonism Relat Disord; 2015 Jan; 21(1):50-4. PubMed ID: 25466406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
[TBL] [Abstract][Full Text] [Related]
7. Utility of movement disorder society-unified Parkinson's disease rating scale for evaluating effect of subthalamic nucleus deep brain stimulation.
Yamamoto T; Yamanaka Y; Hirano S; Higuchi Y; Kuwabara S
Front Neurol; 2022; 13():1042033. PubMed ID: 36686507
[TBL] [Abstract][Full Text] [Related]
8. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.
Goetz CG; Stebbins GT; Tilley BC
Mov Disord; 2012 Sep; 27(10):1239-42. PubMed ID: 22886777
[TBL] [Abstract][Full Text] [Related]
9. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
10. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.
Rodriguez-Blazquez C; Rojo-Abuin JM; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG; Martinez-Martin P
Parkinsonism Relat Disord; 2013 Oct; 19(10):889-93. PubMed ID: 23791519
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
Front Neurol; 2021; 12():705407. PubMed ID: 34659081
[No Abstract] [Full Text] [Related]
12. Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings.
Rodríguez-Blázquez C; Alvarez M; Arakaki T; Campos Arillo V; Chaná P; Fernández W; Garretto N; Martínez-Castrillo JC; Rodríguez-Violante M; Serrano-Dueñas M; Ballesteros D; Rojo-Abuin JM; Ray Chaudhuri K; Merello M; Martínez-Martín P
Mov Disord Clin Pract; 2017; 4(4):529-535. PubMed ID: 30363416
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease.
Sun BH; Wang T; Li NY; Wu Q; Qiao J
World J Gastrointest Pharmacol Ther; 2021 Jan; 12(1):21-31. PubMed ID: 33564494
[TBL] [Abstract][Full Text] [Related]
14. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
Holden SK; Finseth T; Sillau SH; Berman BD
Mov Disord Clin Pract; 2018; 5(1):47-53. PubMed ID: 29662921
[TBL] [Abstract][Full Text] [Related]
15. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS.
Rodriguez-Blazquez C; Schrag A; Rizos A; Chaudhuri KR; Martinez-Martin P; Weintraub D
Mov Disord Clin Pract; 2021 Feb; 8(2):231-239. PubMed ID: 33553493
[TBL] [Abstract][Full Text] [Related]
17. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Goetz CG; Tilley BC; Shaftman SR; Stebbins GT; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stern MB; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; van Hilten JJ; LaPelle N;
Mov Disord; 2008 Nov; 23(15):2129-70. PubMed ID: 19025984
[TBL] [Abstract][Full Text] [Related]
18. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.
Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Sakakibara R; Shimo Y; Hattori N; Kuwabara S; Yamamoto T; Kaji Y; Hirano S; Kadowaki T; Hirata K;
J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):953-959. PubMed ID: 28847794
[TBL] [Abstract][Full Text] [Related]
19. Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study.
Ueno T; Kon T; Haga R; Nishijima H; Arai A; Tomiyama M
Neurol Sci; 2020 Oct; 41(10):2867-2873. PubMed ID: 32328832
[TBL] [Abstract][Full Text] [Related]
20. Handling missing values in the MDS-UPDRS.
Goetz CG; Luo S; Wang L; Tilley BC; LaPelle NR; Stebbins GT
Mov Disord; 2015 Oct; 30(12):1632-8. PubMed ID: 25649812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
